The Biden administration proposed expanding coverage of weight loss medication to Medicaid and Medicare recipients. RFK Jr.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Musk’s push for affordable GLP-1 medications comes as lawmakers on both sides have sought expanded coverage for weight loss ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

On Christmas Day, Elon Musk turned heads with a decadent photo by his tree. Dressed head-to-toe in a Santa costume, he ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

The amount of health care Minnesotans got in 2022 didn’t grow much from the year before — but the amount they paid for it sure did. Health care spending increased 15% from 2021 to 2022, reaching ...

Medicare recipients will see a major change as out-of-pocket prescription drug costs are capped at $2,000 per year under the ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

In 2024, new medicines changed how we think about healthy weight loss—but psychological factors remain just as important as ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...